These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 20233112)

  • 1. Assessment and rehabilitation of cognitive impairment in multiple sclerosis.
    Messinis L; Kosmidis MH; Lyros E; Papathanasopoulos P
    Int Rev Psychiatry; 2010; 22(1):22-34. PubMed ID: 20233112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment in multiple sclerosis.
    Patti F
    Mult Scler; 2009 Jan; 15(1):2-8. PubMed ID: 18805842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive dysfunction in multiple sclerosis: the effect of pharmacological interventions.
    Lyros E; Messinis L; Papageorgiou SG; Papathanasopoulos P
    Int Rev Psychiatry; 2010; 22(1):35-42. PubMed ID: 20222786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cognitive impairment].
    Reuter F; Audoin B; Rico A; Malikova I; Ranjeva JP; Pelletier J
    Rev Neurol (Paris); 2009 Mar; 165 Suppl 4():S113-22. PubMed ID: 19361675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in multiple sclerosis: effects of current treatment options.
    Kargiotis O; Paschali A; Messinis L; Papathanasopoulos P
    Int Rev Psychiatry; 2010; 22(1):67-82. PubMed ID: 20233115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations.
    Rogers JM; Panegyres PK
    J Clin Neurosci; 2007 Oct; 14(10):919-27. PubMed ID: 17659875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are there protective treatments for cognitive decline in MS?
    Amato MP; Portaccio E; Zipoli V
    J Neurol Sci; 2006 Jun; 245(1-2):183-6. PubMed ID: 16643949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between cognitive impairment and quality of life in patients with early multiple sclerosis.
    Glanz BI; Healy BC; Rintell DJ; Jaffin SK; Bakshi R; Weiner HL
    J Neurol Sci; 2010 Mar; 290(1-2):75-9. PubMed ID: 19944429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease progression in pediatric multiple sclerosis: disparities between physical and neurocognitive outcomes.
    Yeh EA; Parrish JB; Weinstock-Guttman B
    Expert Rev Neurother; 2011 Mar; 11(3):433-40. PubMed ID: 21375448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The possibilities of neuropsychological rehabilitation in multiple sclerosis].
    Rosti-Otajärvi E; Hämäläinen P
    Duodecim; 2010; 126(24):2845-52. PubMed ID: 21268907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuropsychological evaluation and psychopathology of multiple sclerosis].
    Defer G
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1128-34. PubMed ID: 11787345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cognitive and emotional disorders in multiple sclerosis. Can a management strategy be envisioned?].
    Pelletier J; Benoit N; Montreuil M; Habib M
    Pathol Biol (Paris); 2000 Mar; 48(2):121-31. PubMed ID: 10815288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S; Vardi J; Finkelstein Y; Pollak L
    Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cognitive burden of multiple sclerosis in children.
    Banwell BL; Anderson PE
    Neurology; 2005 Mar; 64(5):891-4. PubMed ID: 15753431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive functioning in multiple sclerosis.
    Julian LJ
    Neurol Clin; 2011 May; 29(2):507-25. PubMed ID: 21439456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychological aspects of childhood multiple sclerosis: an overview.
    Blaschek A; Storm van's Gravesande K; Heinen F; Pritsch M; Mall V; Calabrese P
    Neuropediatrics; 2012 Aug; 43(4):176-83. PubMed ID: 22605613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cognitive impairment in patients with multiple sclerosis.
    Patti F
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1679-99. PubMed ID: 22876911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis.
    Porcel J; Montalban X
    J Neurol Sci; 2006 Jun; 245(1-2):177-81. PubMed ID: 16674980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-induced plasticity of cognitive functions in MS patients: insights from fMRI.
    Penner IK; Kappos L; Rausch M; Opwis K; Radü EW
    J Physiol Paris; 2006 Jun; 99(4-6):455-62. PubMed ID: 16713204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.